Replies to post #171397 on Biotech Values

[DewDiligence]

Re: MNTA-AnaptysBio drug-discovery deal

Presumably a novel drug, and not a biosimilar, as AnaptysBio has a core expertise in the immuno-onc space. Would be interesting to see MNTA pursuing this space given the buzz for PD-1, etc.

The PR uses the phrase novel antibodies, so this collaboration is definitely not about FoB’s. Your guess vis-à-vis immuno-oncology is as good as any, IMO.

[DewDiligence]

MNTA exercises AnaptysBio option to further IVIG program:

http://finance.yahoo.com/news/momenta-pharmaceuticals-exercises-option-acquire-123000665.html

Momenta Pharmaceuticals, Inc…today announced that it has exercised its option to acquire novel antibodies generated by AnaptysBio, Inc., a privately-held therapeutic antibody company, as part of the previously announced agreement between the two companies.

"The antibodies generated by AnaptysBio allow us to further progress our development of a novel recombinant antibody for certain autoimmune disorders," said Ganesh Kaundinya, Ph.D., Chief Scientific Officer of Momenta Pharmaceuticals, Inc. "The target for the antibodies was selected based on Momenta's research of the complex biology underlying the anti-inflammatory effects of IVIg. As a result of this research, we engaged AnaptysBio to engineer a novel recombinant antibody that targets a specific biological pathway we believe is important for autoimmune diseases.

We look forward to sharing more details of this program and our other lead programs in the autoimmune disease area at our R&D day in October.

MNTA’s R&D Day is on 10/10/14.

[DewDiligence]

ANAB files S-1 for IPO:

http://finance.yahoo.com/news/anaptysbio-files-registration-statement-proposed-210000997.html

AnaptysBio is an antibody development company focused on novel programs in inflammation and immuno-oncology. The Company's proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and severe adult peanut allergy, and ANB019, an anti-IL-36 receptor antibody initially being developed for the treatment of generalized pustular psoriasis.

AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery, which is designed to replicate key features of the human immune system and overcomes limitations of prior antibody technologies.

AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Celgene and Tesaro.